Biological evaluation of 2,3-dioxoindolin-N-phenylacetamide derivatives as potent CDC25B and PTP1B phosphatase inhibitors. Brazilian Journal of Pharmaceutical Sciences, [S. l.], v. 56, p. e00222, 2020. DOI: 10.1590/s2175-97902019000400222. Disponível em: https://www.revistas.usp.br/bjps/article/view/181157.. Acesso em: 8 may. 2024.